白蛋白-球蛋白比值和白蛋白-球蛋白评分在多发性骨髓瘤患者中的预后价值。
Prognostic value of the albumin-globulin ratio and albumin-globulin score in patients with multiple myeloma.
机构信息
Department of Hematology, The Affiliated Jiangyin Hospital of Southeast University Medical College, Jiangyin, Jiangsu, China.
Department of Nephrology, The Affiliated Jiangyin Hospital of Southeast University Medical College, Jiangyin, Jiangsu, China.
出版信息
J Int Med Res. 2021 Mar;49(3):300060521997736. doi: 10.1177/0300060521997736.
OBJECTIVE
The albumin-globulin ratio (AGR) has been identified as a promising prognostic predictor of mortality in patients with hematological malignancies. This study investigated the prognostic significance of AGR in patients with multiple myeloma.
METHODS
Two hundred patients diagnosed with multiple myeloma from January 2010 to October 2018 were retrospectively analyzed and followed up until December 2019. Kaplan-Meier curves and multivariate Cox regression analysis were applied to detect the prognostic value of AGR.
RESULTS
The median follow-up period was 36 months. The optimal cutoff of AGR was 1.16 according to receiver operating characteristic curve analysis. High AGR was significantly correlated with better overall survival (OS) and progression-free survival (PFS). Multivariate analysis revealed that low AGR was an independent prognostic factor for worse OS (hazard ratio [HR] = 1.82, 95% confidence interval [CI] = 1.15-2.94) and PFS (HR = 1.53, 95% CI = 1.09-2.17).
CONCLUSIONS
AGR may represent a potential prognostic biomarker in patients with multiple myeloma. We demonstrated that high AGR was associated with a favorable overall survival and progression-free survival in patients with multiple myeloma.
目的
白蛋白-球蛋白比值（AGR）已被确定为血液恶性肿瘤患者死亡的有前途的预后预测指标。本研究调查了 AGR 在多发性骨髓瘤患者中的预后意义。
方法
回顾性分析了 2010 年 1 月至 2018 年 10 月期间诊断为多发性骨髓瘤的 200 例患者，并随访至 2019 年 12 月。采用 Kaplan-Meier 曲线和多变量 Cox 回归分析检测 AGR 的预后价值。
结果
中位随访时间为 36 个月。根据受试者工作特征曲线分析，AGR 的最佳截断值为 1.16。高 AGR 与更好的总生存期（OS）和无进展生存期（PFS）显著相关。多变量分析显示，低 AGR 是 OS（风险比[HR] = 1.82，95%置信区间[CI] = 1.15-2.94）和 PFS（HR = 1.53，95% CI = 1.09-2.17）较差的独立预后因素。
结论
AGR 可能是多发性骨髓瘤患者的潜在预后生物标志物。我们表明，高 AGR 与多发性骨髓瘤患者的总体生存和无进展生存相关。
Zotero 插件